{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T05:02:12Z","timestamp":1784869332434,"version":"3.55.0"},"reference-count":32,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T00:00:00Z","timestamp":1784851200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004837","name":"Ministerio de Ciencia e Innovaci\u00f3n","doi-asserted-by":"publisher","award":["PDC2022-133713-I00, CPP2022-009838, RED2022-134750-T"],"award-info":[{"award-number":["PDC2022-133713-I00, CPP2022-009838, RED2022-134750-T"]}],"id":[{"id":"10.13039\/501100004837","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000780","name":"European Commission","doi-asserted-by":"publisher","award":["SGL2103020"],"award-info":[{"award-number":["SGL2103020"]}],"id":[{"id":"10.13039\/501100000780","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100012818","name":"Comunidad de Madrid","doi-asserted-by":"publisher","award":["IND2019\/BMD-17219, S2022\/BMD-7278"],"award-info":[{"award-number":["IND2019\/BMD-17219, S2022\/BMD-7278"]}],"id":[{"id":"10.13039\/100012818","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","award":["PI24\/00925"],"award-info":[{"award-number":["PI24\/00925"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Eculizumab, a humanized monoclonal antibody targeting the complement protein C5, is highly efficient in paroxysmal nocturnal hemoglobinuria, atypical hemolytic uremic syndrome, generalized myasthenia gravis, and neuromyelitis optica spectrum disorder. However, recent reports have highlighted a subset of patients who show inadequate treatment response, prompting dose escalation or interval shortening. The serum concentration required for sustained inhibition of the complement lytic pathway remains uncertain, and the commonly cited 50\u2013100 \u00b5g\/ml range is not grounded in robust pharmacokinetic\u2013pharmacodynamic data. Using publicly available clinical data digitized from four rare indications, we trained machine-learning supervised classifiers to predict complete C5 inhibition as a function of serum eculizumab concentration, identifying logistic regression on log-transformed concentration as the best and mechanistically appropriate model on real data. We then examined whether augmenting the real training data with high-fidelity synthetic data improves the resulting estimate. Although augmentation did not significantly change balanced accuracy, it reduced the confidence interval for the effective concentration by roughly 12-fold (a 92% reduction). The augmentation-stabilized estimate of the concentration associated with complete C5 inhibition was approximately 310.8\u2013335.2 \u00b5g\/ml (real-data-only estimate 338 \u00b5g\/ml, 95% CI 275\u2013454). These data-driven, hypothesis-generating results indicate that current maintenance targets aimed at near-complete C5 suppression may be substantially underestimated and that faithful synthetic augmentation can improve the precision of model-based pharmacological estimates in rare diseases; prospective validation in independent cohorts is required before any clinical application.<\/jats:p>","DOI":"10.3389\/fimmu.2026.1800803","type":"journal-article","created":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T04:23:34Z","timestamp":1784867014000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Data-augmented machine learning refines the effective-concentration estimate for eculizumab in complement-mediated diseases"],"prefix":"10.3389","volume":"17","author":[{"given":"Francisco J.","family":"Fern\u00e1ndez","sequence":"first","affiliation":[{"name":"Dep. Molecular and Cellular Biosciences, Centro de Investigaciones Biol\u00f3gicas Margarita Salas (CIB-CSIC), Consejo Superior de Investigaciones Cient\u00edficas","place":["Madrid, Spain"]},{"name":"Abvance Biotech SL, Pharmacokinetics, Pharmacodynamics & Drug Metabolism (PPDM)","place":["Madrid, Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luc\u00eda","family":"Alfonso-Gonz\u00e1lez","sequence":"additional","affiliation":[{"name":"Dep. Molecular and Cellular Biosciences, Centro de Investigaciones Biol\u00f3gicas Margarita Salas (CIB-CSIC), Consejo Superior de Investigaciones Cient\u00edficas","place":["Madrid, Spain"]},{"name":"Abvance Biotech SL, Pharmacokinetics, Pharmacodynamics & Drug Metabolism (PPDM)","place":["Madrid, Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manuel","family":"Praga","sequence":"additional","affiliation":[{"name":"Department of Medicine, Complutense University","place":["Madrid, Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaare","family":"Mikkelsen","sequence":"additional","affiliation":[{"name":"Department of Electrical and Computer Engineering, Aarhus University","place":["Aarhus, Denmark"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. Cristina","family":"Vega","sequence":"additional","affiliation":[{"name":"Dep. Molecular and Cellular Biosciences, Centro de Investigaciones Biol\u00f3gicas Margarita Salas (CIB-CSIC), Consejo Superior de Investigaciones Cient\u00edficas","place":["Madrid, Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,7,24]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1007\/s40262-019-00742-8","article-title":"Pharmacology, pharmacokinetics and pharmacodynamics of eculizumab, and possibilities for an individualized approach to eculizumab","volume":"58","author":"Wijnsma","year":"2019","journal-title":"Clin Pharmacokinet"},{"key":"B2","unstructured":"SOLIRIS- Eculizumab Injection, Solution, Concentrate\n          \n          2022"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-017-2924-y","article-title":"Serologic response to meningococcal vaccination in patients with paroxysmal nocturnal hemoglobinuria (PNH) chronically treated with the terminal complement inhibitor eculizumab","volume":"96","author":"Alashkar","year":"2017","journal-title":"Ann Hematol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1007\/s00467-014-2990-5","article-title":"Eculizumab hepatotoxicity in pediatric aHUS","volume":"30","author":"Hayes","year":"2015","journal-title":"Pediatr Nephrol Berl Ger"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1016\/j.nefro.2017.10.001","article-title":"Hepatotoxicity associated with eculizumab in a patient with atypical hemolytic uremic syndrome","volume":"38","author":"Oruc","year":"2018","journal-title":"Nefrologia"},{"key":"B6","unstructured":"Soliris: Epar-Product Information\n          \n          2023"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-06-094136","article-title":"Multicenter phase 3 study of the complement inhibitor eculizumab for the treatment of patients with paroxysmal nocturnal hemoglobinuria","volume":"111","author":"Brodsky","year":"2008","journal-title":"Blood"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1111\/cei.12890","article-title":"Monitoring of complement activation biomarkers and eculizumab in complement-mediated renal disorders","volume":"187","author":"Wehling","year":"2017","journal-title":"Clin Exp Immunol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2014-3503","article-title":"Case report: Benefits and challenges of long-term eculizumab in atypical hemolytic uremic syndrome","volume":"135","author":"Cullinan","year":"2015","journal-title":"Pediatrics"},{"key":"B10","article-title":"Synthetic Data -- what, why and how","volume-title":"ArXiv.","author":"Jordon","year":"2022"},{"key":"B11","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1038\/s41746-025-01749-1","article-title":"Few shot learning for phenotype-driven diagnosis of patients with rare genetic diseases","volume":"8","author":"Alsentzer","year":"2025","journal-title":"NPJ Digit Med"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2020.36220","article-title":"Machine learning of patient characteristics to predict admission outcomes in the Undiagnosed Diseases Network","volume":"4","author":"Amiri","year":"2021","journal-title":"JAMA Netw Open"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1007\/s40614-021-00284-0","article-title":"Validity and reliability analysis of the PlotDigitizer software program for data extraction from single-case graphs","volume":"45","author":"Aydin","year":"2021","journal-title":"Perspect Behav Sci"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1093\/comjnl\/14.4.422","article-title":"An algorithm with guaranteed convergence for finding a zero of a function","volume":"14","author":"Brent","year":"1971","journal-title":"Comput J"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1038\/s41592-019-0686-2","article-title":"SciPy 1.0: fundamental algorithms for scientific computing in Python","volume":"17","author":"Virtanen","year":"2020","journal-title":"Nat Methods"},{"key":"B16","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1023\/A:1012299115260","article-title":"Ways to fit a PK model with some data below the quantification limit","volume":"28","author":"Beal","year":"2001","journal-title":"J Pharmacokinet Pharmacodyn"},{"key":"B17","first-page":"242","volume-title":"Python 3 Reference Manual","author":"Van Rossum","year":"2009"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2021.696385","article-title":"Eculizumab pharmacokinetics and pharmacodynamics in patients with generalized myasthenia gravis","volume":"12","author":"Monteleone","year":"2021","journal-title":"Front Neurol"},{"key":"B19","article-title":"Scikit-learn: machine learning in Python","author":"Pedregosa","year":"2011","journal-title":"ArXiv"},{"key":"B20","doi-asserted-by":"crossref","DOI":"10.1145\/2939672.2939785","article-title":"XGBoost: a scalable tree boosting system","author":"Chen","year":"2016"},{"key":"B21","first-page":"399","article-title":"The synthetic data vault","author":"Patki","year":"2016"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.48550\/arXiv.1610.06545","article-title":"Revisiting classifier two-sample tests","author":"Lopez-Paz","year":"2018"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.99.6.1211","article-title":"Immunochemical quantitation of the third, fourth and fifth components of human complement: concentrations in the serum of healthy adults","volume":"99","author":"Kohler","year":"1967","journal-title":"J Immunol"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V118.21.1034.1034","article-title":"Efficacy and safety of eculizumab in children and adolescents with paroxysmal nocturnal hemoglobinuria","volume":"118","author":"Reiss","year":"2011","journal-title":"Blood"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-03-560540","article-title":"Assessing complement blockade in patients with paroxysmal nocturnal hemoglobinuria receiving eculizumab","volume":"125","author":"Peffault de Latour","year":"2015","journal-title":"Blood"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1208981","article-title":"Terminal complement inhibitor eculizumab in atypical hemolytic-uremic syndrome","volume":"368","author":"Legendre","year":"2013","journal-title":"N Engl J Med"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1002\/ccr3.628","article-title":"Maintenance eculizumab dose adjustment in the treatment of atypical hemolytic uremic syndrome: a case report and review of the literature","volume":"4","author":"Thomson","year":"2016","journal-title":"Clin Case Rep"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-02-333997","article-title":"Long-term treatment with eculizumab in paroxysmal nocturnal hemoglobinuria: sustained efficacy and improved survival","volume":"117","author":"Kelly","year":"2011","journal-title":"Blood"},{"key":"B29","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1111\/ejh.12021","article-title":"Predictors of hemoglobin response to eculizumab therapy in paroxysmal nocturnal hemoglobinuria","volume":"90","author":"DeZern","year":"2013","journal-title":"Eur J Haematol"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1016\/j.kint.2015.11.026","article-title":"Eculizumab is a safe and effective treatment in pediatric patients with atypical hemolytic uremic syndrome","volume":"89","author":"Greenbaum","year":"2016","journal-title":"Kidney Int"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.686","article-title":"Eculizumab dosing regimen in atypical HUS: possibilities for individualized treatment","volume":"102","author":"Volokhina","year":"2017","journal-title":"Clin Pharmacol Ther"},{"key":"B32","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1111\/bph.70054","article-title":"C-model: a comprehensive enhanced pharmacokinetic\/pharmacodynamic simulation environment targeting the complement system","volume":"1","author":"Alfonso-Gonz\u00e1lez","year":"2025","journal-title":"Br J Pharmacol"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1800803\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T04:23:37Z","timestamp":1784867017000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1800803\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,24]]},"references-count":32,"alternative-id":["10.3389\/fimmu.2026.1800803"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1800803","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,24]]},"article-number":"1800803"}}